Tachycardia Detection Algorithm Discriminating SVT and VT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current implantable cardioverter defibrillators face challenges in accurately distinguishing between supraventricular tachycardia (SVT) and ventricular tachycardia (VT), leading to inappropriate therapy delivery and potential battery inefficiency due to the similarity in tachycardia cycle lengths and retrograde conduction patterns.
Innovation Solution
A tachycardia detection algorithm utilizing dual-vector EGM sensing to estimate heart rates and apply beat-by-beat rules for discriminating between VT and SVT, incorporating RR interval analysis and morphology scoring to accurately classify rhythms and guide appropriate therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If tachycardia detection relies on cycle length alone, then detection simplicity is maintained, but discrimination accuracy between SVT and VT deteriorates
Solution Approach 1:
The patent segments the tachycardia detection process into multiple independent analysis dimensions: cycle length analysis, morphology analysis, and conduction pattern analysis. Each dimension provides partial information, and their combination enables accurate SVT/VT discrimination without requiring any single complex measurement system.
Solution Approach 2:
The patent transitions from one-dimensional cycle length measurement to multi-dimensional analysis by incorporating morphology features (waveform shape, amplitude, duration) and conduction pattern characteristics (retrograde P-waves, ventricular activation sequences). This dimensional expansion resolves the accuracy limitation of cycle length alone.
2Reliability
If high-voltage cardioversion shocks are delivered for all tachycardias, then therapy effectiveness is maximized, but battery consumption and patient discomfort increase
Solution Approach 1:
The patent applies partial action by delivering less aggressive therapy (anti-tachycardia pacing) for SVT instead of excessive high-voltage shocks. The therapy intensity is matched to the arrhythmia type: SVT receives pacing therapy while VT receives shock therapy, avoiding unnecessary high-energy delivery for non-life-threatening conditions.
Solution Approach 2:
The patent changes the therapy parameter (energy level) based on the detected arrhythmia type. SVT detection triggers low-energy pacing parameters, while VT detection triggers high-energy shock parameters. This parameter adaptation ensures effective therapy while minimizing unnecessary battery consumption.
3Speed
If aggressive shock therapy is used immediately, then termination of tachycardia is achieved quickly, but patient pain and battery depletion occur
Solution Approach 1:
The patent performs preliminary classification of the tachycardia type (SVT vs. VT) before delivering therapy. This preliminary action enables selection of the most appropriate therapy modality, avoiding unnecessary patient discomfort from painful shocks for SVT and preventing battery depletion from ineffective high-energy delivery.
Solution Approach 2:
The patent uses feedback from multiple signal analyses (cycle length, morphology, conduction patterns) to guide therapy selection. The system continuously monitors EGM signals, compares them against SVT/VT characteristics, and adjusts therapy delivery based on this feedback, ensuring rapid termination with minimal patient discomfort.
Data Source
AI summary
A medical device and associated method for discriminating cardiac events includes determining whether a first match score is within a first match zone having a first correlation with a non-treatable cardiac event, a second match zone having a second correlation with the non-treatable cardiac event less than the first correlation with the non-treatable event, a third match zone having a first correlation with a treatable cardiac event, and a fourth match zone having a second correlation with the treatable cardiac event greater than the first correlation with the treatable cardiac event. A determination is made as to whether a second match score and a third match score are within the first match zone, the second match zone, the third match zone and the fourth match zone to generate a first adjusting factor, and cardiac event evidence is accumulated in response to the first adjusting factor for discriminating cardiac events.